Jabil upgraded by UBS as AI demand, healthcare growth support outlook
UBS upgraded Jabil Inc (JBL) to Buy and raised estimates, saying a multiyear growth cycle is supported by AI investment, healthcare demand, and expanding automation and robotics. UBS set a $430 price target and lowered its valuation multiple to about 22x. It forecasts AI revenue growth to about $20.3B in FY2027, raised EPS to $16.78 (FY2027) and $20.24 (FY2028).
How this was made
The 30-second read
Why it matters
The analyst upgrade raises forward EPS and expects AI-related revenue growth of at least ~50% in fiscal 2027, while also pointing to healthcare margin expansion tied to the Croatia facility repurposing.
Market read
This is a single-name catalyst driven by a fresh sell-side rating change and explicit forward estimate revisions, which can move positioning even without new company fundamentals.
What to watch
Customer roadmap dependence (Amazon, Meta) and the pace of healthcare capacity ramp could be the swing factors; any delays would weaken the margin expansion path into FY27-28.
Background
UBS frames Jabil’s outlook around a multiyear growth cycle from AI investment, healthcare demand, and expanding automation/robotics markets.
Ticker impact
UBS upgraded Jabil to Buy, raised FY27/FY28 EPS, and set a $430 target citing AI-driven growth and healthcare capacity ramp.
Likely supportive for the next several sessions as traders price in the raised estimates and the unchanged but re-anchored P/E multiple.
The article provides specific analyst actions (rating, PT, EPS numbers) and a concrete thesis (AI revenue growth, Croatia healthcare capacity, margin expansion), which typically drives incremental positioning even without new company filings.
Market effects
Supports the broader electronics/EMS and automation/robotics capex read-through tied to AI infrastructure buildouts.
Mentions capacity expansion in Memphis and North Carolina, which may reinforce confidence in US manufacturing utilization trends.
AI infrastructure demand and healthcare outsourcing capacity are global themes that can influence peer sentiment across contract manufacturing.
Counterpoint
The unchanged $430 target despite higher EPS implies the multiple compression is doing most of the work, so upside may be capped if de-rating persists.
Key entities
- public_companyJabil Inc
Subject of the article; UBS upgraded to Buy, raised estimates, and set a $430 price target.
- analyst_firmUBS
Issued the upgrade, raised EPS estimates, and provided the valuation multiple and growth/margin thesis.
